Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 26, 2024
Daily News
June 26, 2024
- Health Minister Set to Meet Generic Execs to Hear Views on Industry Revamp
June 26, 2024
- TGCV Drug CNT-01 Misses Goal in Japan PIIb/III Study: Toa Eiyo
June 26, 2024
- Tagrisso Plus Chemo Now Allowed to Treat EGFR Lung Cancer: AstraZeneca
June 26, 2024
- JCR, Takeda End Global Collab for Hunter Syndrome Therapy
June 26, 2024
- Rexulti’s PTSD Filing Clinches FDA Acceptance for Review: Otsuka/Lundbeck
June 26, 2024
- Santen CEO Snares 191 Million Yen in Annual Pay, Workforce Down by 131
June 26, 2024
- Finnish Pharma Orion Poised for Japan Debut with Reacquisition of Parkinson’s Meds This Year
June 26, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…